Editing Openai/693cca0d-8c24-800e-bde2-ffa4c902003d (section)

=== Why cannabinoids can be neuroprotective ===
# Antioxidant + anti-inflammatory actions. CBD and other cannabinoids reduce oxidative stress and neuroinflammation in multiple preclinical models (stroke, TBI, Alzheimer’s/Parkinson’s models) and modulate pathways that prevent cell death. Those mechanisms are the biological basis for calling cannabinoids “neuroprotective antioxidants.” (Most of this evidence is preclinical, with growing human-targeted research.) PMC<ref>{{cite web|title=PMC|url=https://pmc.ncbi.nlm.nih.gov/articles/PMC9932048/|publisher=pmc.ncbi.nlm.nih.gov|access-date=2025-12-13}}</ref>
# Balanced 1:1 THC:CBD has clinical precedent. A 1:1 THC:CBD oromucosal spray (nabiximols / Sativex) has been studied and used clinically for MS spasticity and neuropathic symptoms in many countries — showing therapeutic benefit with an improved side-effect profile versus THC alone, which supports the idea that pairing CBD with THC can increase benefit and reduce some adverse effects. That’s why many people favor a 1:1 oil for therapeutic use. Dove Medical Press<ref>{{cite web|title=Dove Medical Press|url=https://www.dovepress.com/a-review-of-scientific-evidence-for-thccbd-oromucosal-spray-nabiximols-peer-reviewed-fulltext-article-JPR|publisher=Dove Medical Press|access-date=2025-12-13}}</ref>
# Route matters. Non-smoked delivery (oils, tinctures, vaporized isolates, microemulsions) avoids combustion products (tar, polycyclic aromatic hydrocarbons) and is far more appropriate when comparing to alcohol in terms of systemic risk.